Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

Delayed Quote. Delayed  - 09/26 03:47:41 pm
96.8 USD   -0.62%
09/22 NASDAQ 100 MOVE : Bmrn, bbby
09/21DJSAREPTA THERAPE : to Sell Up to $225 Million of Stock
09/21 BIOMARIN PHARMA : Reviews Status of Exon 51 Composition of Matter an..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo BioMarin Pharmaceutical In
Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.

It operates its business through one segment, the biopharmaceutical development and commercialization segment.

Its company's products include Naglazyme, Kuvan, Aldurazyme, Firdapse and VIMIZIM.

The company was founded on March 21, 1997 and is headquartered in Novato, CA.

Number of employees : 2 158 persons.
Sales per Businesses
20142015Delta
USD (in Million)%USD (in Million)%
Biopharmaceutical Development and Commercialization751.04100.1%889.90102% +18.49%
Sales per Regions
20142015Delta
USD (in Million)%USD (in Million)%
United States380.0450.7%444.0850.9% +16.85%
Europe139.9418.7%178.7520.5% +27.73%
Latin America118.5615.8%142.3116.3% +20.03%
Rest of World112.4915%124.7714.3% +10.91%
Managers
NameAgeSinceTitle
Jean-Jacques Bienaimé622005Chairman & Chief Executive Officer
Daniel K. Spiegelman, MBA572012Chief Financial Officer & Executive Vice President
Henry J. Fuchs, MD582009Chief Medical Officer & Executive Vice President
Eduardo E. Von Pervieux, MBA-2008Chief Information Officer & Vice President
Pierre LaPalme752004Director
Elaine J. Heron PhD, MBA682002Independent Non-Executive Director
Michael G. Grey632005Independent Non-Executive Director
Richard A. Meier562006Lead Independent Non-Executive Director
V. Bryan Lawlis Jr., PhD642007Independent Non-Executive Director
Alan J. Lewis, PhD702005Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 170,782,081 170,170,606 99.6% 0 0.0% 99.6%
Shareholders
NameEquities%
Capital Research & Management Co. (Global Investors) 15,853,303 9.28%
The Vanguard Group, Inc. 11,448,690 6.70%
Sands Capital Management LLC 10,918,317 6.39%
Fidelity Management & Research Co. 9,970,031 5.84%
Jennison Associates LLC 9,051,244 5.30%
BlackRock Fund Advisors 7,655,321 4.48%
PRIMECAP Management Co. 7,319,319 4.29%
Baker Bros. Advisors LP 4,806,483 2.81%
T. Rowe Price Associates, Inc. 3,525,314 2.06%
Temasek Holdings Pte Ltd. (Investment Management) 3,472,712 2.03%
Holdings
NameEquities%Valuation
Catalyst Pharmaceuticals Inc (CPRX) 6,666,6678.04%6,733,334 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Generic Pharmaceuticals
Advertisement
Sector Generic Pharmaceuticals
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICA..-7.03%16 634
SUN PHARMACEUTICAL IND..-5.02%28 165
OTSUKA HOLDINGS CO LTD5.19%25 163
ONO PHARMACEUTICAL CO...-37.03%15 857
ASPEN PHARMACARE HOLDI..5.62%10 757
TAISHO PHARMACEUTICAL ..21.23%9 166
SHANGHAI FOSUN PHARMAC..3.19%8 192
CIPLA LTD-6.38%7 378
CADILA HEALTHCARE LIMI..0.00%6 063
HANMIPHARM--.--%5 736
DIVI'S LABORATORIES LT..15.65%5 317
ENDO INTERNATIONAL PLC-61.79%5 211
CHINA MEDICAL SYSTEM H..20.42%4 422
SHENZHEN SALUBRIS PHAR..--.--%4 392
HUNAN ER-KANG PHARMACE..--.--%4 316
GLENMARK PHARMACEUTICA..2.43%4 003
RICHTER GEDEON VEGYESZ..--.--%3 892
ZHEJIANG NHU COMPANY L..--.--%3 718
HUBEI JUMPCAN PHARMACE..5.10%3 529
STADA ARZNEIMITTEL AG34.17%3 506
HUAPONT LIFE SCIENCES ..--.--%2 908
Sector Generic Pharmaceuticals
BioMarin Pharmaceutical In : Connections
Algorithme Pharma, Inc.
Amplyx Pharmaceuticals, Inc.
Sutro Biopharma, Inc.
Reneo Pharmaceuticals, Inc.
AbSci LLC
Ziarco Group Ltd.
Ziarco Pharma Ltd.
Zephyrus Biosciences, Inc.
Rincon Pharmaceuticals, Inc.
Itero Biopharmaceuticals LLC
GLyPharma Therapeutic, Inc.
Reform Biologics LLC
Targazyme, Inc.
Batu Biologics, Inc.
GlycoFi, Inc.
Cytochroma, Inc.
DiaVacs, Inc.
Pediapharm Inc
Cellastra, Inc.
A. M. Pappas & Associates LLC
Biotechnology Innovation Organization
Rapidscan Pharma Solutions, Inc.
Sosei Co. Ltd.
Selventa, Inc.
Balance Therapeutics, Inc.
Capella Therapeutics, Inc.
Company contact information
770 street Lindaro
CA 94901 San Rafael, California
États-Unis (les)

Phone : +1 415 506 6700
Fax : +1 415 382 7889
Internet : http://www.bmrn.com
Markets and indexes
- NASDAQ All Markets
- Nasdaq Global Select Market
- Nasdaq 100 /
Stock Exchange Codes
- ISIN Code :  US09061G1013
- Bloomberg Code :  
- Reuters Code :  BMRN.O
- Datastream Code :  
© 2016 People , Fundamentals and Ownership    © 2016 Cofisem